The value of Integrated Evidence Planning in China

Published on June 11, 2026

Explore how pharmaceutical companies can align evidence generation across key stages of the product lifecycle to maximize the value for innovative medicines in China. Real-world case studies highlight effective approaches and success factors.

In China's increasingly complex pharmaceutical market, generating more evidence does not necessarily translate into greater product value. Despite substantial investments in clinical and real-world evidence (RWE), pharmaceutical companies often struggle to ensure that evidence generation is aligned with long-term business objectives, addresses the evolving needs of stakeholders across the product lifecycle, and is effectively coordinated across internal functions. As a result, critical evidence gaps persist, resources are spread across disconnected initiatives, and opportunities to accelerate approval, reimbursement, and market access may be missed.

Integrated Evidence Planning (IEP) is becoming a strategic…

Simon-Kucher insights: How to maximize the value of IEP in China

Continue reading on website
Other news

Customer development: Executing profitable growth in wholesale and distribution into realized growth

June 10, 2026
Wholesalers and distributors are becoming increasingly sophisticated in how they segment customers and differentiate pricing. But differentiated GTM execution and customer development often lag, with many wholesalers and distributors relying on broadly similar coverage and activities across customers that have different needs and growth potential. The commercial challenge across wholesale and dist

Neobanking in the UK: Growth, limits, and what comes next

July 1, 2026
The UK has produced some of the world’s most successful neobanks, but domestic growth tells a more nuanced story. New results from our Neobanking Study reveal why high adoption has not yet translated into product depth and business model maturity, and what this means for the next phase of competition.The UK’s place in a global neobanking shiftGlobally, neobanks have moved beyond challenger status.